Blab News
Precigen Secures 7-Year FDA Orphan Drug Exclusivity for PAPZIMEOS, Strengthening RRP Treatment Landscape
On June 15, Precigen Inc. (NASDAQ:PGEN) announced that the U.S. Food and Drug Administration had granted its precision medicine PAPZIMEOS an orphan‑drug exclusivity designation, giving the company a seven‑year period during which the FDA cannot approve a comparable therapy. The exclusivity will run through August 2032, extending the company’s market advantage for its treatment of adult recurrent respiratory papillomatosis (RRP).
PAPZIMEOS is a non‑replicating adenoviral vector‑based immunotherapy built on Precigen’s proprietary AdenoVerse platform. The therapy delivers a modified adenovirus that trains the immune system to recognize and destroy the human papillomavirus (HPV) types 6 and 11, the strains that cause most adult RRP cases. The drug is already available across the United States and is given by subcutaneous injection.
The orphan‑drug designation is reserved for treatments that address conditions affecting fewer than 200,000 people in the U.S. RRP is a rare disease that often forces patients to undergo repeated surgical procedures to remove benign tumors from the airway. By offering a durable medical solution, PAPZIMEOS can reduce the frequency of these surgeries.
During the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Precigen presented long‑term durability data from its pivotal study. According to the company, 83 % of patients who achieved a complete response remained surgery‑free for at least 36 months without additional treatment. Five patients were reported to have stayed surgery‑free beyond four years.
The exclusivity award follows the drug’s full FDA approval, which was granted after a confirmatory clinical trial demonstrated safety and efficacy. Precigen’s commercial success with PAPZIMEOS contributed to a revenue increase in the first quarter of 2026, as noted in the company’s earnings call. CEO Helen Sabzevari said the exclusivity period would support continued investment in the product’s commercialization and the potential expansion into other indications.
Headquartered in Germantown, Maryland, Precigen—formerly Intrexon Corporation—has developed the AdenoVerse platform to deliver genes efficiently. Beyond PAPZIMEOS, the platform could be applied to other gene and cell therapies, vaccines, and antiviral treatments.
The orphan‑drug exclusivity is a significant milestone for Precigen because it protects the company’s investment in a therapy that tackles a rare but debilitating disease. The exclusivity window also offers a period in which the company can establish a robust commercial presence and negotiate reimbursement arrangements with payors. While the RRP market is small, the therapy’s impact on patient quality of life and on healthcare costs is substantial.
At present, PAPZIMEOS remains the only FDA‑approved immunotherapy for adult RRP. Precigen is monitoring post‑marketing data and will continue to engage with regulatory agencies to ensure ongoing safety and efficacy. The company has indicated that it will explore additional indications for its AdenoVerse platform, but no specific timelines have been announced.
In summary, Precigen’s receipt of FDA orphan‑drug exclusivity for PAPZIMEOS extends the company’s market advantage through 2032, supports its financial performance, and reinforces the therapeutic value of a precision medicine that reduces the surgical burden for patients with a rare respiratory disease.
PAPZIMEOS is a non‑replicating adenoviral vector‑based immunotherapy built on Precigen’s proprietary AdenoVerse platform. The therapy delivers a modified adenovirus that trains the immune system to recognize and destroy the human papillomavirus (HPV) types 6 and 11, the strains that cause most adult RRP cases. The drug is already available across the United States and is given by subcutaneous injection.
The orphan‑drug designation is reserved for treatments that address conditions affecting fewer than 200,000 people in the U.S. RRP is a rare disease that often forces patients to undergo repeated surgical procedures to remove benign tumors from the airway. By offering a durable medical solution, PAPZIMEOS can reduce the frequency of these surgeries.
During the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Precigen presented long‑term durability data from its pivotal study. According to the company, 83 % of patients who achieved a complete response remained surgery‑free for at least 36 months without additional treatment. Five patients were reported to have stayed surgery‑free beyond four years.
The exclusivity award follows the drug’s full FDA approval, which was granted after a confirmatory clinical trial demonstrated safety and efficacy. Precigen’s commercial success with PAPZIMEOS contributed to a revenue increase in the first quarter of 2026, as noted in the company’s earnings call. CEO Helen Sabzevari said the exclusivity period would support continued investment in the product’s commercialization and the potential expansion into other indications.
Headquartered in Germantown, Maryland, Precigen—formerly Intrexon Corporation—has developed the AdenoVerse platform to deliver genes efficiently. Beyond PAPZIMEOS, the platform could be applied to other gene and cell therapies, vaccines, and antiviral treatments.
The orphan‑drug exclusivity is a significant milestone for Precigen because it protects the company’s investment in a therapy that tackles a rare but debilitating disease. The exclusivity window also offers a period in which the company can establish a robust commercial presence and negotiate reimbursement arrangements with payors. While the RRP market is small, the therapy’s impact on patient quality of life and on healthcare costs is substantial.
At present, PAPZIMEOS remains the only FDA‑approved immunotherapy for adult RRP. Precigen is monitoring post‑marketing data and will continue to engage with regulatory agencies to ensure ongoing safety and efficacy. The company has indicated that it will explore additional indications for its AdenoVerse platform, but no specific timelines have been announced.
In summary, Precigen’s receipt of FDA orphan‑drug exclusivity for PAPZIMEOS extends the company’s market advantage through 2032, supports its financial performance, and reinforces the therapeutic value of a precision medicine that reduces the surgical burden for patients with a rare respiratory disease.
